Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Executive summary: nicotine addiction.

Ann I Graul1, J R Prous

  • 1Prous Science, Barcelona, Spain. journals@prous.com

Drugs of Today (Barcelona, Spain : 1998)
|August 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Year's New Drugs & Biologics - 2009.

Drug news & perspectives·2010
Same author

Overcoming the obstacles in the pharma/biotech industry: 2009 update.

Drug news & perspectives·2010
Same author

The year's new drugs & biologics - 2008.

Drug news & perspectives·2009
Same author

Promoting, improving and accelerating the drug development and approval processes.

Drug news & perspectives·2009
Same author

Overcoming the obstacles in the pharma/biotech industry: 2008 update.

Drug news & perspectives·2009
Same author

The year's new drugs and biologics--2007.

Drug news & perspectives·2008
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Nicotine addiction remains a global health crisis, causing millions of preventable deaths annually. Combining pharmacotherapy and behavioral therapy is the most effective approach for smoking cessation and managing nicotine withdrawal symptoms.

Area of Science:

  • Public Health
  • Addiction Medicine
  • Pharmacology

Background:

  • Nicotine addiction is a widespread global health issue, with smoking being the leading cause of preventable death in many countries.
  • The World Health Organization reports nearly 5 million tobacco-related deaths annually, with half of all smokers dying from their addiction.
  • Despite awareness, tobacco use persists, highlighting the urgent need for effective smoking cessation strategies.

Purpose of the Study:

  • To review current and emerging pharmacotherapies and behavioral therapies for smoking cessation.
  • To identify novel drug targets and therapeutic vaccines in development for nicotine addiction treatment.
  • To emphasize the importance of combination therapy for managing nicotine withdrawal.

Main Methods:

Related Experiment Videos

  • Review of existing literature on smoking cessation pharmacotherapies, including nicotine replacement therapy (NRT) and bupropion hydrochloride.
  • Exploration of ongoing research into new drug targets such as nicotinic acetylcholine, cannabinoid, dopamine, and opioid receptors.
  • Examination of the development pipeline for therapeutic vaccines aimed at nicotine addiction.

    • Main Results:

    • Combination therapy of pharmacotherapy and behavioral therapy is the most effective strategy for smoking cessation.
    • Nicotine replacement therapy (NRT) and sustained-release bupropion hydrochloride are established pharmacotherapies.
    • New therapeutic avenues targeting various neurotransmitter receptors and vaccine development show promise for future treatments.

    Conclusions:

    • Effective smoking cessation relies on a combination of pharmacotherapy and behavioral interventions to manage nicotine withdrawal.
    • Current and emerging pharmacotherapies, alongside novel drug targets and vaccines, offer hope for improved nicotine addiction treatment.
    • Continued research and development are crucial to combat the global burden of tobacco-related disease and death.